Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.14 USD | -1.72% | -0.87% | -35.96% |
03-14 | Transcript : Protalix BioTherapeutics, Inc., 2023 Earnings Call, Mar 14, 2024 | |
03-14 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Business Summary
Number of employees: 208
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Recombinant Therapeutic Proteins
100.0
%
| 48 | 100.0 % | 38 | 100.0 % | -19.50% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Global
56.3
%
| 22 | 46.9 % | 22 | 56.3 % | -3.33% |
United States
26.5
%
| 12 | 26.0 % | 10 | 26.5 % | -18.08% |
Brazil
16.7
%
| 9 | 19.8 % | 6 | 16.7 % | -32.29% |
Italy
0.5
%
| 3 | 7.2 % | 0 | 0.5 % | -94.50% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 57 | 29/06/19 |
Eyal Rubin
DFI | Director of Finance/CFO | 48 | 21/07/19 |
Yael Hayon
CTO | Chief Tech/Sci/R&D Officer | 41 | 04/07/20 |
Yaron Naos
COO | Chief Operating Officer | 60 | 31/12/03 |
Gina Balderas
PRN | Corporate Officer/Principal | - | - |
Fellous Yael
HRO | Human Resources Officer | - | 31/07/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Pol Boudes
BRD | Director/Board Member | 67 | 30/11/19 |
Gwen Melincoff
BRD | Director/Board Member | 72 | 30/11/19 |
Aharon Schwartz
BRD | Director/Board Member | 80 | 31/10/14 |
Amos Bar Shalev
BRD | Director/Board Member | 71 | 30/06/08 |
Eliot Forster
CHM | Chairman | 58 | 13/09/23 |
Shmuel Ben Zvi
BRD | Director/Board Member | 64 | 29/06/22 |
Dror Bashan
CEO | Chief Executive Officer | 57 | 29/06/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 73,316,084 | 66,179,744 ( 90.27 %) | 0 | 90.27 % |
Company contact information
Protalix Biotherapeutics, Inc.
2 University Plaza Suite 100
07601, Hackensack
+972 4 902 8100
http://www.protalix.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.96% | 83.58M | |
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- PLX Stock
- Company Protalix BioTherapeutics, Inc.